The IPO Buzz: ADARx Pharmaceuticals Upsizes IPO & Prices It At $17 – High End

San Diego-based biotechnology firm ADARx Pharmaceuticals, Inc. has officially priced its upsized initial public offering (IPO) at $17.00 per share—the ceiling of its previously target range of $15.00 to $17.00.

Strong institutional demand prompted the company to expand the offering from 21.88 million to 26.25 million shares, raising $446.25 million in gross proceeds. The stock debuted on the Nasdaq Global Select Market under the ticker symbol ADRX.

1. Key Offering Terms & Deal Mechanics

IPO Share Price: $17.00 per share (High end of $15.00 – $17.00 range)
Total Primary Shares Sold: 26,250,000 shares (Upsized from 21.88M)
Gross IPO Proceeds: ~$446.25 Million
Underwriter Greenshoe: 30-day option for up to an additional 3,937,500 shares
Market Capitalization at Listing: ~$1.81 Billion
Joint Book-Running Managers: J.P. Morgan, Morgan Stanley, TD Cowen, UBS Investment Bank, and LifeSci Capital

┌────────────────────────────────────────────────────────────────────────┐
│                   ADARX PHARMACEUTICALS (ADRX) IPO                     │
├─────────────────────────┬──────────────────────────────────────────────┤
│ Metric                  │ Detail / Value                               │
├─────────────────────────┼──────────────────────────────────────────────┤
│ Ticker Symbol           │ NASDAQ: ADRX                                 │
│ Final Offer Price       │ $17.00 per share (High end)                  │
│ Shares Issued           │ 26.25 Million (Upsized from 21.88M)          │
│ Direct IPO Capital      │ $446.25 Million                              │
│ Strategic Investment    │ $100.00 Million (AbbVie Concurrent Private)  │
│ Total Gross Proceeds    │ ~$535.25 Million                             │
│ Initial Debut Trading   │ Opened at $22.10 (+30% initial pop)          │
└─────────────────────────┴──────────────────────────────────────────────┘

2. Strategic Backing: The AbbVie Partnership

Adding significant credibility to the offering, pharmaceutical giant AbbVie (NYSE: ABBV) purchased $100 million of ADARx common stock in a concurrent private placement at the $17.00 IPO price.

This private placement expands AbbVie’s existing multi-year collaboration with ADARx—focused on developing novel therapies across neuroscience, immunology, and oncology—giving AbbVie a ~4.9% equity stake in the company post-offering. Combined, the IPO and private placement delivered $535.2 million in fresh capital before underwriter option execution.

3. Technology Pipeline: Next-Gen RNA Interference (siRNA)

ADARx is targeting genetic, complement-mediated, and central nervous system disorders using proprietary small interfering RNA (siRNA) platforms designed to silence disease-causing genes before targeted proteins can form.

Lead Asset — Onvuzosiran (Late-Stage Clinical): An siRNA therapeutic targeting hereditary angioedema (HAE) entering Phase 3 trials. Early clinical trials demonstrated up to a 93% reduction in plasma kallikrein, the protein responsible for severe swelling episodes.
Agazisiran (Phase 2 Clinical): Targeting complement-mediated diseases, including IgA nephropathy, geographic atrophy, and paroxysmal nocturnal hemoglobinuria.
Preclinical & Early Pipeline: Next-generation RNAi programs targeted toward metabolic conditions (obesity) and neurodegenerative conditions like Alzheimer’s disease.

4. Market Performance & Biotech Sentiment

The strong pricing and immediate secondary market demand highlight a broader revival in institutional risk appetite for late-stage clinical biotechs:

- Advertisement -

Trading Debut: ADRX opened on the secondary market at $22.10, surging 30% above its initial $17.00 offering price before settling around $19.35 on its first day.
Capital Runway: The combined $535M capital injection provides ADARx with runway through late-stage Phase 3 clinical readouts anticipated in 2027.